JPY 4,779.00
+50.00 (+1.06%)
JPY · as of 2026-08-18 · marketstack
| Size & multiples | |||
| Market Cap | JPY 1.39T | Enterprise Value | JPY 1.33T |
| P/E (TTM) | — | PEG (trailing) | — |
| P/S | 1.69× | P/FCF | 18.18× |
| EV/EBITDA | 15.95× | EV/EBIT | 30.23× |
| EV/Sales | 1.62× | EV/FCF | 17.40× |
| FCF Yield | 5.50% | Buyback Yield | — |
| Owner Earnings Yield | — | Shareholder Yield | — |
| Cost of capital & EVAmethodology → | |||
| Beta (5y monthly) | −0.15 | Risk-free (assumed) | 4.00% |
| Equity risk premium (assumed) | 4.23% | Cost of Equity | — |
| After-tax Cost of Debt | 2.28% | WACC | — |
| ROIC | 4.24% | EVA Spread (ROIC−WACC) | — |
| EVA | — | ||
Flows latest annual · EPS TTM — · revenue TTM JPY 825.38B · FCF TTM JPY 76.68B (in JPY)
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
| Metric | Today | Own median | Own range | %ile | z | Sector med. | mo · distinct |
|---|---|---|---|---|---|---|---|
| P/E | 34.57× | only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one. | |||||
| 4.4% | — | no band (13 mo · 2 distinct) | — | — | −36.9% | 13 · 2 | |
| 4.2% | — | no band (13 mo · 2 distinct) | — | — | −15.4% | 13 · 2 | |
| 4.7% | — | no band (13 mo · 2 distinct) | — | — | −21.3% | 13 · 2 | |
| 6.1% | −3.6% | 61st | −0.06σ | 5.1% | 141 · 141 | ||
| EPS Growth 3Y | −10.9% | only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one. | |||||
| 3.5% | — | no band (13 mo · 2 distinct) | — | — | 9.0% | 13 · 2 | |
| Market Cap | $8.67B | not reconstructed — market cap was removed from the historical pass (never a ranking factor, and a reconstructed share count carries look-ahead risk). The single stored value is the forward-captured snapshot, not a series. | |||||
shown for reference only — the reconstructed distribution did not clear the band gate, so no rank is quoted.
Filed earnings only.
no P/E ladder — only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
Not a forecast: each row re-prices today's filed earnings at a multiple this company itself once traded at. It abstains rather than guess on a loss year or a broken per-share basis.
Every month uses only what was filed by then, split-adjusted. Delisted names are absent and a trough year can throw one huge reading, so read the median, not the edges.
Loading the monthly cohort placement…
Cheap vs Health Care on EV/EBITDA; rich on P/E
P/E 69th · EV/EBITDA 50th pct
Whole-sector pool — median skews small.
| Metric | This (FY) | Peer median | IQR (25–75) | %ile |
|---|---|---|---|---|
| P/E | 34.6x | 26.0x | 13.7x–39.9x | 69 ↑rich |
| EV/EBITDA | 15.8x | 15.9x | 9.9x–28.0x | 50 ↓cheap |
| EV/Sales | 1.6x | 3.3x | 1.7x–7.9x | 24 ↓cheap |
| FCF Yield | 5.6% | -7.2% | -32.9%–1.4% | 89 ↑strong |
| Dividend Yield | 3.3% | 1.0% | 0.2%–2.4% | 85 ↑strong |
| Net Margin | 4.7% | -21.3% | -329.2%–7.1% | 71 ↑strong |
| Operating Margin | 5.3% | -34.7% | -552.6%–8.0% | 71 ↑strong |
| ROE | 4.4% | -36.9% | -92.5%–4.5% | 75 ↑strong |
Reading the covered industry pool…
Held-with peers…
Peers by disclosure language…
This company has no published industry pool year: either its industry group is untagged in our universe, we hold no annual revenue for it, or its group's newest year has not cleared the filing-alignment guard yet. This is a coverage gap, not a statement about the company.